| |
|
Product Name:
|
Peptide Pool, SARS-Related Coronavirus 2 Non-Structural Protein 12 (NSP12)
|
|
Ownership statement:
|
This reagent is the property of the U.S. Government.
|
|
Manufacturer:
|
Biosynth International, Inc.
|
|
Material Provided:
|
NR-56791 contains 1 vial of lyophilized peptides, containing 50 µg of each peptide, 9.25 mg total peptide.
|
|
Packing/Storage:
|
Lyophilized peptides should be placed in a closed, dry environment with desiccants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.
|
|
Reconstitution:
|
Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.
The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water. Peptides that are not soluble in water can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. For cell based assays, 0.5% DMSO in medium is usually well tolerated.
Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help dissolution. These solvents may not be appropriate for certain applications, including cell-based assays.
|
|
Solubility:
|
Some peptides need DMSO for solubility, and the final pool is soluble in DMSO.
|
|
Storage of Reconstituted Peptides:
|
The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5-6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Zhou, P., et al. “A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin.” Nature 579 (2020): 270-273. PubMed: 32015507.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Peptide Pool, SARS-Related Coronavirus 2 Non-Structural Protein 12 (NSP12), NR-56791.”
|
|
Biosafety Level:
|
1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|